Literature DB >> 30917006

The Kinome of Human Alveolar Type II and Basal Cells, and Its Reprogramming in Lung Cancer.

Sonia M Leach1,2, Jay Finigan3, Vihas T Vasu4, Rangnath Mishra3, Moumita Ghosh3, Daniel Foster3, Robert Mason3, Beata Kosmider5,6,7, Eveline Farias Hesson2, Jeffrey A Kern3.   

Abstract

The discovery of mutant tyrosine kinases as oncogenic drivers of lung adenocarcinomas has changed the basic understanding of lung cancer development and therapy. Yet, expressed kinases (kinome) in lung cancer progenitor cells, as well as whether kinase expression and the overall kinome changes or is reprogrammed upon transformation, is incompletely understood. We hypothesized that the kinome differs between lung cancer progenitor cells, alveolar type II cells (ATII), and basal cells (BC) and that their respective kinomes undergo distinct lineage-specific reprogramming to adenocarcinomas and squamous cell carcinomas upon transformation. We performed RNA sequencing on freshly isolated human ATII, BC, and lung cancer cell lines to define the kinome in nontransformed cells and transformed cells. Our studies identified a unique kinome for ATII and BC and changes in their kinome upon transformation to their respective carcinomas.

Entities:  

Keywords:  alveolar type II cells; basal cells; kinome; lung adenocarcinoma; lung squamous cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 30917006      PMCID: PMC6775950          DOI: 10.1165/rcmb.2018-0283OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  53 in total

1.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.

Authors:  Gurkan Mollaoglu; Matthew R Guthrie; Stefanie Böhm; Johannes Brägelmann; Ismail Can; Paul M Ballieu; Annika Marx; Julie George; Christine Heinen; Milind D Chalishazar; Haixia Cheng; Abbie S Ireland; Kendall E Denning; Anandaroop Mukhopadhyay; Jeffery M Vahrenkamp; Kristofer C Berrett; Timothy L Mosbruger; Jun Wang; Jessica L Kohan; Mohamed E Salama; Benjamin L Witt; Martin Peifer; Roman K Thomas; Jason Gertz; Jane E Johnson; Adi F Gazdar; Robert J Wechsler-Reya; Martin L Sos; Trudy G Oliver
Journal:  Cancer Cell       Date:  2017-01-12       Impact factor: 31.743

2.  Differentiated human alveolar epithelial cells and reversibility of their phenotype in vitro.

Authors:  Jieru Wang; Karen Edeen; Rizwan Manzer; Yongsheng Chang; Shuanglin Wang; Xueni Chen; C Joel Funk; Gregory P Cosgrove; Xiaohui Fang; Robert J Mason
Journal:  Am J Respir Cell Mol Biol       Date:  2007-01-25       Impact factor: 6.914

Review 3.  Isolation and culture of alveolar type II cells.

Authors:  L G Dobbs
Journal:  Am J Physiol       Date:  1990-04

4.  Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.

Authors:  Barbara A Helfrich; Jihye Kim; Dexiang Gao; Daniel C Chan; Zhiyong Zhang; Aik-Choon Tan; Paul A Bunn
Journal:  Mol Cancer Ther       Date:  2016-08-05       Impact factor: 6.261

5.  Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.

Authors:  Jacqueline M Mason; Xin Wei; Graham C Fletcher; Reza Kiarash; Richard Brokx; Richard Hodgson; Irina Beletskaya; Mark R Bray; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-07       Impact factor: 11.205

6.  Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.

Authors:  Jihye Kim; Vihas T Vasu; Rangnath Mishra; Katherine R Singleton; Minjae Yoo; Sonia M Leach; Eveline Farias-Hesson; Robert J Mason; Jaewoo Kang; Preveen Ramamoorthy; Jeffrey A Kern; Lynn E Heasley; James H Finigan; Aik Choon Tan
Journal:  Bioinformatics       Date:  2014-05-07       Impact factor: 6.937

7.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

8.  Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice.

Authors:  R R Tönjes; J Löhler; J F O'Sullivan; G F Kay; G H Schmidt; W Dalemans; A Pavirani; D Paul
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

9.  Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes.

Authors:  A Ehrhardt; T Bartels; A Geick; R Klocke; D Paul; R Halter
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

10.  Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.

Authors:  Yuehong Wang; Ratnakar Singh; Liguang Wang; Monique Nilsson; Ruchitha Goonatilake; Pan Tong; Lerong Li; Uma Giri; Pamela Villalobos; Barbara Mino; Jaime Rodriguez-Canales; Ignacio Wistuba; Jing Wang; John V Heymach; Faye M Johnson
Journal:  Oncotarget       Date:  2016-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.